Semler Scientific, Inc.: management transactions · United States · SEC (Form 4)

About Semler Scientific, Inc.

Semler Scientific, Inc. (ticker: SMLR) is a U.S.-listed medical technology company trading on the NASDAQ in the United States. Headquartered in Campbell, California, United States, the company develops, manufactures, and markets products and services designed to support the early detection and treatment of chronic diseases, with a primary focus on cardiovascular and metabolic conditions. Its core historical asset is QuantaFlo®, a patented, FDA-cleared point-of-care test that measures arterial blood flow in the extremities and helps clinicians quickly assess the presence of peripheral arterial disease, including in asymptomatic patients. The company was co-founded in 2007 by Dr. Herbert J. Semler and has built its business around diagnostic technology intended to fit into routine clinical workflows. From a competitive standpoint, Semler Scientific occupies a specialized niche within chronic-disease diagnostics. Rather than competing as a broad-based medtech platform, it focuses on a narrower set of solutions where speed, ease of use, and clinical utility matter. QuantaFlo is central to the company’s value proposition, and its ability to produce results in minutes supports adoption in physician offices, care networks, and other healthcare settings. The company has also introduced adjacent software and data-oriented offerings aimed at supporting disease evaluation, treatment, and practice management, although the flagship diagnostic product remains the main commercial reference point. Its operating footprint is concentrated in the United States, where it maintains its headquarters and where most of its commercial and regulatory activity is centered. Recent developments have materially shaped the investment case. Semler Scientific has drawn attention for adopting Bitcoin as its primary treasury reserve asset, making it one of the better-known U.S. public corporate Bitcoin holders. That strategy has given the stock a distinctive profile, but it also introduces balance-sheet volatility and a more complex capital-allocation framework. In 2025, the company remained active in capital markets, including convertible debt and at-the-market financing activity. A major recent milestone was the announced merger agreement with Strive, Inc., which shareholders approved in January 2026 and which was completed shortly thereafter, signaling a significant strategic transition for the business. For investors, SMLR has therefore evolved from a single-product medtech story into a more unusual public-market case that combines healthcare diagnostics, treasury-asset strategy, and corporate restructuring on the NASDAQ in the United States.